Bell, et al. Appl. No. 09/664,444 Page 2

In the Claims:


Please cancel claims 20-23.

Please amend claims 1, 24-26 and 34 as follows:

0

- 1. (Amended) A method of reducing the viability of a tumor cell, comprising administering to the tumor cell a virus, wherein said virus is a vesicular stomatitis virus and said tumor cell is a hematopoietic tumor cell.
- 5. The method of claim 1, wherein the tumor cell is a hematopoietic cancer cell.
- 6. The method of claim 5, wherein the hematopoietic cancer cell is a leukemia, a lymphoma, or a myeloma.
- 7. The method of claim 6, wherein the hematopoietic cancer cell is a leukemia.
- 8. The method of claim 7, wherein the leukemia is acute myelogenous leukemia.
- 9. The method of claim 7, wherein the leukemia is chronic myelogenous leukemia.
- 10. The method of claim 7, wherein the leukemia is promyelocytic leukemia.
- 11. The method of claim 7, wherein the leukemia is T cell leukemia.
- 12. The method of claim 6, wherein the hematopoietic cancer cell is a lymphoma.

- 13. The method of claim 6, wherein the hematopoietic cancer cell is a myeloma.
- 18. The method of claim 1, wherein the tumor cell has substantially no PKR activity.
- 19. The method of claim 1, wherein the tumor cell is PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.
- 24. (Amended) The method of claim 7, further comprising administering interferon to the tumor cell prior to administering VSV.



- 26. (Amended) The method of claim 5, wherein the virus is an attenuated strain of vesicular stomatitis virus.
- 27. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M1.
- 28. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M2.
- 29. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M3.
- 30. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M4.

Bell, et al. Appl. No. 09/664,444 Page 4

- 31. The method of claim 26, wherein the virus is vesicular stomatitis virus strain M5.
- 32. The method of claim 1, wherein the tumor cell is in a mammalian subject and the virus is administered to the tumor cell by intravenous, intranasal, intraperitoneal or intratumoral administration to the subject.
- 33. The method of claim 32, wherein the mammalian subject is a human or a non-human mammal.

03

- 34. (Amended) The method of claim 32, wherein the virus is contained in cell line infected with the virus and the administration comprises administering the virus-infected cell line to the subject by a route selected from intratumorally, intravenously and intraperitoneally.
- 35. A method of reducing the viability of a tumor cell within a population of tumor cells and non-tumor cells comprising administering a vesicular stomatitis virus to the population of cells, wherein the virus is able to selectively infect and kill the tumor cell.
- 36. The method of claim 35, wherein the virus is unable to inactivate PKR activity in the tumor cell.
- 37. The method of claim 36, further comprising treating the population of cells with interferon prior to administering the virus.